Michael Bass, MD
Gastroenterology · Wilmington, DENPI 1841451580
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 40.6% of the total. Reporting peaked in 2019 at $3,436 and has fallen 69.7% since, to $1,041 in 2025. Among gastroenterology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $45.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$335
- Capsopro Services LLC$300
- Madrigal Pharmaceuticals$255
- plus $1K from 20 others
Across 1 payment — averaging $16,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$16K
What the payments were for
- Consulting fees$4,70042%
- Speaking & faculty fees$2,60023%
- Food & beverage$3,81434%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $4,512 |
| AbbVie(2 entities) | 63 | $3,241 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 72 | $1,070 |
| Johnson & Johnson | 19 | $335 |
| Capsopro Services LLC | 1 | $300 |
| Madrigal Pharmaceuticals | 9 | $255 |
| Stryker | 1 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $203 |
| Pfizer | 6 | $113 |
| Phathom Pharmaceuticals, Inc. | 7 | $101 |
| Bristol Myers Squibb | 6 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $80 |
| Intercept Pharmaceuticals, Inc. | 4 | $73 |
| Ardelyx, Inc. | 4 | $73 |
| Lilly USA, LLC | 4 | $71 |
| Sanofi | 4 | $70 |
| Ironwood Pharmaceuticals, Inc | 3 | $43 |
| Amgen | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $39 |
| Braintree Laboratories, Inc. | 3 | $38 |
| Gilead | 2 | $32 |
| Novo Nordisk | 2 | $32 |
| Boston Scientific | 2 | $30 |
| Vivus LLC | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,120 in reported general payments places this provider in the 90th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $148,066 |
| LinzessLinaclotide | 108 | $122,643 |
| Humira PenAdalimumab | 13 | $92,247 |
| XifaxanRifaximin | 27 | $83,104 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 530 | $31,164 |
| ViberziEluxadoline | 13 | $19,755 |
| MotegrityPrucalopride Succinate | 17 | $18,484 |
| Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br | 46 | $15,197 |
| Omeprazole | 753 | $12,631 |
| Sucralfate | 76 | $9,048 |
| Dicyclomine Hcl | 337 | $8,602 |
| Lubiprostone | 47 | $7,203 |
| Dexlansoprazole DrDexlansoprazole | 22 | $6,392 |
| Lansoprazole | 58 | $5,214 |
| Mesalamine | 14 | $4,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Viberzi | $3,241 | $142,398121 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,070 | $83,10427 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $203 | $18,48417 claims |
| Braintree Laboratories, Inc.Sutab | $38 | $4,47028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 gastroenterology providers in Delaware.
Other gastroenterology in Wilmington
- Donald GirardWilmington$8K
- Pedro DayritWilmington$1K
- Michael BrooksNewark$48K
- Abhishek AgnihotriDover$28K
- Richard CarusoLewes$13K
- Bhavin DaveDover$11K
- Christopher RuffiniNeward$11K
- Jorge UribeNewark$11K
- Laura ConnorNewark$11K
- Gaurav JainNewark$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.